UBS Group’s POMDOCTOR LIMITED Class A Ordinary Shares POM Stock Holding History

UBS Group’s Portfolio POM Stock Details POM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.02K	Buy	3,463 +2,538	+274%	+$9.7K	﹤0.01%	8977
2026 Q1	$4.28K	Sell	925 -11,367	-92%	-$58.3K	﹤0.01%	8952
2025 Q4	$65.3K	Buy	+12,292	New	+$802K	﹤0.01%	7095

Other funds holding POM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

UBS Group's POM Position: Q2 2026 in Review

UBS Group increased its POMDOCTOR LIMITED Class A Ordinary Shares (POM) stake by 274% in Q2 2026, buying an estimated $9.7K and bringing the position to 3,463 shares worth $5.02K. The position accounts for ﹤0.01% of the portfolio, ranked #8977.

UBS Group first reported a position in POM in Q4 2025 and has held it in 3 quarters since. The position peaked at $65.3K in Q4 2025. 6 funds tracked by Wall St. Rank hold POM as of Q2 2026.

UBS Group held 3,463 shares of POMDOCTOR LIMITED Class A Ordinary Shares worth $5.02K as of Q2 2026.
UBS Group bought 2,538 POMDOCTOR LIMITED Class A Ordinary Shares shares in Q2 2026, an estimated $9.7K.
POMDOCTOR LIMITED Class A Ordinary Shares made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8977 holding.
UBS Group first reported a position in POMDOCTOR LIMITED Class A Ordinary Shares in Q4 2025 and has held it in 3 quarters since.
UBS Group's POMDOCTOR LIMITED Class A Ordinary Shares position peaked at $65.3K in Q4 2025.
6 funds tracked by Wall St. Rank held POMDOCTOR LIMITED Class A Ordinary Shares as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.